A
Atef Badran
Researcher at Cairo University
Publications - 3
Citations - 1674
Atef Badran is an academic researcher from Cairo University. The author has contributed to research in topics: Cystectomy & Endometrial cancer. The author has an hindex of 2, co-authored 3 publications receiving 1434 citations.
Papers
More filters
Journal ArticleDOI
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
C Davies,Hongchao Pan,Jon Godwin,Richard Gray,Rodrigo Arriagada,Vinod Raina,Mirta Abraham,Victor Hugo Medeiros Alencar,Atef Badran,Xavier Bonfill,Joan Caroline Bradbury,Mike Clarke,Rory Collins,Susan R. Davis,Antonella Delmestri,John F. Forbes,Peiman Haddad,Ming-Feng Hou,Moshe Inbar,Hussein M. Khaled,Joanna Kielanowska,Wing-Hong Kwan,Beela Sarah Mathew,Indraneel Mittra,Bettina Muller,Antonio Nicolucci,Octavio Peralta,Fany Pernas,Lubos Petruzelka,Tadeusz Pienkowski,Ramachandran Radhika,Balakrishnan Rajan,Maryna Rubach,Sera Tort,Gerard Urrútia,Miriam Valentini,Yaochen Wang,Richard Peto +37 more
TL;DR: Treatment allocation seemed to have no effect on breast cancer outcome among 1248 women with ER-negative disease, and an intermediate effect among 4800 women with unknown ER status, and a further reduction in recurrence and mortality, particularly after year 10.
Journal ArticleDOI
Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Hussein M. Khaled,Hanan E. Shafik,M.S. Zabhloul,M. Ghoneim,R.A. Saber,M. Manie,H.A. Enein,H.A. Megeed,O. Mansur,M.E. Sherbini,T.Z. Mahran,M.E. Kalawee,Atef Badran,Safaa M. Ramadan +13 more
TL;DR: Neoadjuvant GC did not improve survival in locally advanced bladder cancer over radical cystectomy alone, however, bladder preservation was feasible, and OS in responding patients was impressive.
Journal ArticleDOI
A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma
Hussein M. Khaled,Hamdy A. Azim,Emad Barsoum,George Chahine,Ali Shamseddine,Gamal Abdel Metaal,Abbas Omar,Abdul Rahman Jazeih,Rasha Haggag,Atef Badran +9 more
TL;DR: In conclusion, sorafenib was found to be tolerable and effective as first-line therapy in patients with advanced RCC in the Middle East, who were considered to be ineligible for other approved first- line therapies.